ArticleJACC. Case reports2026
Fatal Hypoglycemia in a Nondiabetic Patient With End-Stage Familial Hypertrophic Cardiomyopathy on SGLT2 Inhibitor Therapy.
Article in JACC. Case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSodium-glucose cotransporter 2 inhibitors (SGLT2i) are cornerstone therapies for heart failure, but their safety in extreme clinical scenarios warrants careful evaluation. CASE SUMMARY: A 37-year-old woman with end-stage familial hypertrophic cardiomyopathy and MYH7 mutations developed recurrent hypoglycemia during dapagliflozin therapy. Despite comprehensive guideline-directed therapy, progressive malnutrition (body mass index 18.4 kg/m DISCUSSION: This case demonstrates SGLT2i may precipitate life-threatening hypoglycemia in nondiabetic, malnourished patients with advanced heart failure, particularly when superimposed on end-stage hypertrophic cardiomyopathy's metabolic vulnerability. TAKE-HOME MESSAGES: Enhanced vigilance and regular glucose monitoring are essential when using SGLT2i in high-risk populations. Unexplained hypoglycemia warrants immediate drug discontinuation in vulnerable patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.